Terminated PHASE2 INTERVENTIONAL 1-arm NCT04653389

Perioperative Therapy for Hepatocellular Carcinoma

Perioperative Multidisciplinary Therapy for Technically Resectable Hepatocellular Carcinoma With Vein Thrombosis: An Exploratory Clinical Trail

Sponsor: Zhejiang University

Conditions Hepatocellular Carcinoma

Interventions Radiotherapy Sintilimab Injection TACE

Updated 5 times since 2021 Last updated: Dec 21, 2021 Started: Dec 26, 2020 Primary completion: Oct 1, 2021 Completion: Dec 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The treatment efficacy was not satisfactory.

Other terminated trials from Zhejiang University

See all terminations from Zhejiang University

Other Hepatocellular Carcinoma trials with similar outcome

Browse all Hepatocellular Carcinoma trials

Listed as NCT04653389, this PHASE2 trial focuses on Hepatocellular Carcinoma and remains terminated or withdrawn. Sponsored by Zhejiang University, it has been updated 5 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Feb 2022 — Jul 2024 [monthly]

Terminated PHASE2

Status: Recruiting → Terminated
Mar 2021 — Feb 2022 [monthly]

Recruiting PHASE2
Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE2

First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zhejiang University

Data source: Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China